Videos

Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.

Dr. Hammers summarizes key efficacy findings from the CLEAR study of pembrolizumab + lenvatinib vs sunitinib.

Matthew Matasar, MD, discusses the phase 3 SYMPATICO study of ibrutinib given in combination with venetoclax vs ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.

Analyze the appropriate washout period when switching between KRAS inhibitors.

Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.

Habte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.

Pedro Barata, MD, MSc, FACP, discusses tackling unmet needs in oncology at the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.

Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

A phase 1, first-in-human study is evaluating a novel CAR T-cell therapy in patients with ovarian cancer at Moffitt Cancer Center.

Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.

Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

John Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.

Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.

A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.

Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.

Assess whether the initial therapy aligned with standard guidelines based on disease stage.

Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.